José Luis Martínez-Ordaz1, Ilka Boscó-Gárate2, Arturo Cérbulo-Vázquez3, Lourdes Arriaga-Pizano2, Isabel Wong-Baeza4, Patricio Sánchez-Fernandez1, Constantino López-Macías2, Armando Isibasi2, Eduardo Ferat-Osorio5,6. 1. Servicio de Gastrocirugía, UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México. 2. Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Avenida Cuauhtémoc 330, Colonia Doctores, CP 06720, Ciudad de México, México. 3. División de Enseñanza e Investigación, Hospital de la Mujer, Ciudad de México, México. 4. Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México. 5. Servicio de Gastrocirugía, UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México. eduardoferat@prodigy.net.mx. 6. Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Avenida Cuauhtémoc 330, Colonia Doctores, CP 06720, Ciudad de México, México. eduardoferat@prodigy.net.mx.
Abstract
BACKGROUND: The presence of digestive fistula involves chronic inflammation and fibrosis. It has been reported that ω3-polyunsaturated fatty acids stimulate the resolution of inflammation. AIM: Determine if the administration of oral ω3 reduces fistula output and the time required for fistula closure. METHODS:Forty-nine patients with postoperative fistula were randomly divided in two groups: 26 received conventional treatment and 23 received the conventional treatment supplemented with ω3 (540 mg eicosapentaenoic acid and 360 mg docosahexaenoic acid) for 35 days. Patients were monitored daily for fistula output and spontaneous closure. Additionally, serum pro-inflammatory cytokines and C-reactive protein were quantified in four patients with conventional and in seven patients with ω3 treatment. RESULTS: Patients with ω3 had significantly decreased fistula output from days 2 to 27, compared to control (p < 0.05). Spontaneous fistula closure was achieved in 15 patients (65%) in the ω3 group and in 14 (54%) in the control group. ω3-polyunsaturated fatty intake also decreased the serum concentrations of interleukin-6 and C-reactive protein (p < 0.05). CONCLUSIONS: Our results suggest that ω3 supplementation to conventional medical treatment decreases fistula output and reduces inflammation (interleukin-6 and C-reactive protein), and these effects may increase the efficiency of conventional medical treatment.
RCT Entities:
BACKGROUND: The presence of digestive fistula involves chronic inflammation and fibrosis. It has been reported that ω3-polyunsaturated fatty acids stimulate the resolution of inflammation. AIM: Determine if the administration of oral ω3 reduces fistula output and the time required for fistula closure. METHODS: Forty-nine patients with postoperative fistula were randomly divided in two groups: 26 received conventional treatment and 23 received the conventional treatment supplemented with ω3 (540 mg eicosapentaenoic acid and 360 mg docosahexaenoic acid) for 35 days. Patients were monitored daily for fistula output and spontaneous closure. Additionally, serum pro-inflammatory cytokines and C-reactive protein were quantified in four patients with conventional and in seven patients with ω3 treatment. RESULTS:Patients with ω3 had significantly decreased fistula output from days 2 to 27, compared to control (p < 0.05). Spontaneous fistula closure was achieved in 15 patients (65%) in the ω3 group and in 14 (54%) in the control group. ω3-polyunsaturated fatty intake also decreased the serum concentrations of interleukin-6 and C-reactive protein (p < 0.05). CONCLUSIONS: Our results suggest that ω3 supplementation to conventional medical treatment decreases fistula output and reduces inflammation (interleukin-6 and C-reactive protein), and these effects may increase the efficiency of conventional medical treatment.
Authors: Jose L Martinez; Enrique Luque-de-León; Guillermo Ballinas-Oseguera; José D Mendez; Marco A Juárez-Oropeza; Ruben Román-Ramos Journal: J Gastrointest Surg Date: 2011-10-15 Impact factor: 3.452
Authors: José Luis Martínez-Ordaz; Enrique Luque-de León; Rubén Román-Ramos; Marco Antonio Juárez-Oropeza; José Domingo Méndez-Francisco Journal: Cir Cir Date: 2013 Sep-Oct Impact factor: 0.361
Authors: Thomas-Thi Pluess; Daniel Hayoz; Mette M Berger; Luc Tappy; Jean-Pierre Revelly; Burkhard Michaeli; Yvon A Carpentier; René L Chioléro Journal: Intensive Care Med Date: 2007-03-22 Impact factor: 17.440
Authors: R G J Visschers; S W M Olde Damink; M van Bekkum; B Winkens; P B Soeters; W G van Gemert Journal: Br J Surg Date: 2008-10 Impact factor: 6.939